Pharmaceuticals

Global Alzheimer’s Drugs Market Size Projected to Reach $14.16 Billion During the Forecast Period

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Alzheimer’s Drugs Market Over The Five-Year Period 2025–2029?

The alzheimer’s drugs market size has demonstrated strong growth over recent years. It is projected to expand from $9.33 billion in 2024 to $10.09 billion in 2025, at a compound annual growth rate (CAGR) of 8.1%. The expansion witnessed in the past can be credited to an increase in Alzheimer’s disease cases, significant investments in research and development, an enhanced understanding of disease mechanisms, various global health initiatives, and strengthened public awareness and education.

The alzheimer’s drugs market is anticipated to experience robust expansion over the coming years. This market is projected to reach $14.16 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.8%. Key factors driving this growth during the forecast period include precision medicine approaches, an emphasis on disease modification, the identification and validation of biomarkers, patient-centric drug development, and a focus on non-pharmacological interventions. Significant trends expected during this period involve diverse therapeutic approaches, digital health solutions, regenerative medicine, improvements in diagnostic technologies, the application of artificial intelligence (AI) in drug discovery, and strategic partnerships and collaborations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What Are The Top Growth Drivers Impacting The Alzheimer’s Drugs Market Outlook?

The escalating incidence of Alzheimer’s disease is anticipated to boost the expansion of the Alzheimer’s drugs market moving forward. Alzheimer’s disease is a neurological ailment that progressively worsens, causing both brain shrinkage and the death of brain cells. Medications for Alzheimer’s disease are employed to address memory loss, difficulties with thinking and reasoning, and challenges in performing everyday tasks. These drugs can improve patients’ quality of life and aid in sustaining their independence. For instance, in May 2024, as per a report from the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer’s care, support, and research, the population of Americans aged 65 and older diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the growing prevalence of Alzheimer’s disease is propelling the growth of the Alzheimer’s drugs market.

How Is The Alzheimer’s Drugs Market Segmented?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

Which Trends Are Impacting The Alzheimer’s Drugs Market?

Leading companies in the Alzheimer’s drugs market are developing innovative products, such as amyloid plaque-targeting therapy, to advance treatment options and improve patient outcomes. This therapy represents a treatment approach for Alzheimer’s disease focused on reducing or preventing the accumulation of amyloid-beta plaques in the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, received approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency tasked with protecting public health. Kisunla (donanemab-azbt) is the first and only amyloid plaque-targeting therapy available for early symptomatic Alzheimer’s disease. It functions by assisting the body in eliminating excess amyloid plaques from the brain, which are linked to cognitive decline in Alzheimer’s patients. Kisunla is administered as an intravenous infusion every four weeks. The initial dosing regimen involves 700 mg for the first three doses, followed by 1400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, provided they have confirmed amyloid pathology.

Which Major Firms Are Strengthening Their Position In The Alzheimer’s Drugs Industry?

Major companies operating in the alzheimer’s drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

What Are The Regional Market Dynamics Impacting The Alzheimer’s Drugs Industry?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Alzheimer’s Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

Browse Through More Reports Similar to the Global Alzheimer’s Drugs Market 2025, By The Business Research Company

Neurology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Neurodegenerative Disorder Therapeutic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Neurophysiology Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurophysiology-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795